PepGen has previously faced an FDA clinical hold on the investigational new drug application of PGN-ENO51 in the Phase II ...

US-based CureDuchenne has formed a partnership with Children's Hospital of Orange County (CHOC) to launch a new clinic for ...

Capricor Therapeutics, Inc.'s Deramiocel receives FDA Priority Review for DMD cardiomyopathy, with a decision by Aug. 2025.

While PepGen works to persuade the FDA to let it launch a phase 2 trial of its Duchenne muscular dystrophy (DMD) therapy in ...

Sarepta Therapeutics hits 52-week lows despite strong earnings and growth. Read why investors should view SRPT as a high risk ...

The Food and Drug Administration (FDA) has granted Priority Review to the Biologics License Application (BLA) for deramiocel (CAP-1002) for the treatment ...

Q4 2024 Earnings Call Transcript March 4, 2025 Wave Life Sciences Ltd. beats earnings expectations. Reported EPS is $0.17, expectations were $-0.17. Operator: Good morning and welcome to the Wave Life ...

Activities of daily life, education, and employment were areas of difficulty in the transition to adulthood for patients with ...

Shares of Capricor Therapeutics (CAPR) closed Tuesday with modest gains and rose more than 3% in extended trading after the ...

In the phase 1/2 INSPIRE DUCHENNE trial, interim data showed an average microdystrophin expression of 110% among participants ...

Francisco and Emerald Vargas say their homebound sons dream of seeing the world outside of doctor’s visits and school.

FDA grants Priority Review to Capricor's deramiocel for Duchenne cardiomyopathy, setting an August 2025 decision date with no ...